Citation
Select
RE-DUAL PCI Steering Committee and Investigators; Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
N Engl J Med. 2017 Oct 19;377(16):1513-1524
Citation
Select
COMPASS Investigators; Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
N Engl J Med. 2017 10 05;377(14):1319-1330
Citation
Select
Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, Ayis S
Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
Heart. 2017 Aug 5. doi: 10.1136/heartjnl-2017-311652. [Epub ahead of prin